The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development.
about
The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male miceTranslocator protein (18 kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseasesRegulation of translocator protein 18 kDa (TSPO) expression in health and disease statesTranslocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotraumaTetrapyrroles as Endogenous TSPO Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic LigandsNon-invasive anatomic and functional imaging of vascular inflammation and unstable plaqueThe role of VDAC in cell death: friend or foe?Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesisMitochondria as a target in treatmentRadiolabelled probes for imaging of atherosclerotic plaques.4'-Chlorodiazepam, a translocator protein (18 kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats.Increased plasma levels of endozepines, endogenous ligands of benzodiazepine receptors, during systemic inflammation: a prospective observational studyEndozepine-4 levels are increased in hepatic comaKinetic modelling of [(11)C]PBR28 for 18 kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis.Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.Mitochondrial ion channels.The role of Ets transcription factors in the basal transcription of the translocator protein (18 kDa).Effects of 4'-chlorodiazepam on cellular excitation-contraction coupling and ischaemia-reperfusion injury in rabbit heart.Translocator protein (Tspo) gene promoter-driven green fluorescent protein synthesis in transgenic mice: an in vivo model to study Tspo transcriptionExpression and modulation of translocator protein and its partners by hypoxia reoxygenation or ischemia and reperfusion in porcine renal models.Sex differences in translocator protein 18 kDa (TSPO) in the heart: implications for imaging myocardial inflammation.Functional gains in energy and cell metabolism after TSPO gene insertion.Oxidative stress and cardiac hypertrophy: a review.Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: a review of the literature.The mitochondrial translocator protein and arrhythmogenesis in ischemic heart diseaseTranslocator protein (18 kDa): an update on its function in steroidogenesis.Classical and Novel TSPO Ligands for the Mitochondrial TSPO Can Modulate Nuclear Gene Expression: Implications for Mitochondrial Retrograde Signaling.Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain diseaseThe nitric oxide donor sodium nitroprusside requires the 18 kDa Translocator Protein to induce cell death.TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT.Sodium thiosulphate attenuates brain inflammation induced by systemic lipopolysaccharide administration in C57BL/6J mice.GABAergic modulation with classical benzodiazepines prevent stress-induced neuro-immune dysregulation and behavioral alterations.Is suvorexant a better choice than alternative hypnotics?Clonazepam-associated Bradycardia in a Disabled Elderly Woman with Multiple Complications.Decreases in binding capacity of the mitochondrial 18 kda translocator protein accompany oxidative stress and pathological signs in rat liver after DMBA exposure.Dimethylbenz[alpha]anthracene induces oxidative stress and reduces the binding capacity of the mitochondrial 18-kDa translocator protein in rat aorta.TSPO as a target for treatments of diseases, including neuropathological disorders.Distribution, pharmacological characterization and function of the 18 kDa translocator protein in rat small intestine.TSPO PET Imaging: From Microglial Activation to Peripheral Sterile Inflammatory Diseases?Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities.
P2860
Q21195890-F9B57E87-0FBC-433C-A80E-43F4E49F3ED6Q24602947-7A9F8BF6-BDA8-4A3C-9886-62E89148FB00Q24631648-F54C77E4-D7CD-4B3B-8049-11A286FDEE62Q24649929-ADCF5573-9B35-4F3B-9D2B-25BB34BAD679Q26314612-36A3817A-66CF-40B5-9147-E1258C5463D3Q26824883-97C8250B-4EA2-46D1-A57C-80A3B3926F78Q27010335-C8966DD6-5CF6-40F9-B78C-98EA0F4F8366Q28083751-4F31EEA7-1F35-46BD-8BA0-05DE92B129C0Q28382780-F0F5B2BA-CA6C-4F9E-B6BA-30C6344CEF2DQ30577193-DE16E45A-DD48-45EF-9447-8C9BA806205BQ34111148-BAC88BBE-FC79-475E-AEC4-65D5C1494A25Q35079248-796BAA57-4C85-40D5-9116-BC41827C9F40Q35942406-654444EB-D7E8-4687-881C-020E5932FC3AQ36392550-5F9BBAC4-BD3E-4D3A-B1B4-FA00E83275A7Q36553833-BDF88A55-FC5E-4293-A998-96299B91144CQ36632164-E79CD3DA-CED9-4019-A167-6F0A6556FD1DQ36862917-FD8579BA-28B9-4504-AF70-54E07750B20DQ36926268-A77FB337-DE4A-4D78-8B9D-00AC75940BDDQ37086691-5AF9762F-66AD-402E-BC0A-27CE072D21A3Q37264339-07490EA6-67FC-43FF-9748-E141E4DA6959Q37634177-55745485-4A7B-43AB-8251-B90F98FD8F24Q37701991-8B35F65B-ED32-4587-A0FE-0F0AA2491351Q37991019-90B900EF-2294-47AD-8BAE-2AC73E725800Q38303799-3C46C3FC-1F67-4033-A305-3F3F21C89867Q38445775-BDB8FA84-FB3B-4413-A15F-1D26C23BF39DQ38698954-634C0D4A-5A6C-45EE-8730-36B5E6B93180Q38708545-F7A10CFD-743F-47F1-993D-DEBC2FEC04B1Q38924439-E26C4447-25BC-4338-AC24-D62EB3B59CFAQ39356740-5FC9FAB4-53CD-4555-BEB2-E3B6FC7AC732Q39512498-E7837644-D366-4E38-914A-28225DF53E10Q40205263-BD69157B-371A-4CB9-B29C-D7B60BD65307Q40569952-D2418925-AD55-4BF2-B8BB-2E3A7E80EC56Q40900071-B4740A18-2CD9-4417-B8C5-875423573AABQ42042241-BBD9390E-7CC0-4815-9B47-79F529262164Q42841312-23C339FB-D7B5-4691-B7BA-592F282C3A70Q43021481-0831A0E0-FBB2-4EBC-BD94-9B2E0684D497Q43189292-73D10FDD-08F8-4965-ABB0-BF3EDE520562Q45731942-5D3E8542-8825-4670-B27D-CDDF72F888D6Q47123805-9AECF482-4ED7-46A9-9CC4-04FD73DB2675Q47350689-9B3281B9-5B10-4AA8-9FAB-E6662F57AD98
P2860
The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The peripheral-type benzodiaze ...... ications for drug development.
@ast
The peripheral-type benzodiaze ...... ications for drug development.
@en
The peripheral-type benzodiaze ...... ications for drug development.
@nl
type
label
The peripheral-type benzodiaze ...... ications for drug development.
@ast
The peripheral-type benzodiaze ...... ications for drug development.
@en
The peripheral-type benzodiaze ...... ications for drug development.
@nl
prefLabel
The peripheral-type benzodiaze ...... ications for drug development.
@ast
The peripheral-type benzodiaze ...... ications for drug development.
@en
The peripheral-type benzodiaze ...... ications for drug development.
@nl
P1476
The peripheral-type benzodiaze ...... ications for drug development.
@en
P2093
Leo Veenman
Moshe Gavish
P304
P356
10.1016/J.PHARMTHERA.2005.09.007
P577
2005-12-07T00:00:00Z